ZA202204624B - Long-acting gdf15 fusion protein and pharmaceutical composition comprising same - Google Patents

Long-acting gdf15 fusion protein and pharmaceutical composition comprising same

Info

Publication number
ZA202204624B
ZA202204624B ZA2022/04624A ZA202204624A ZA202204624B ZA 202204624 B ZA202204624 B ZA 202204624B ZA 2022/04624 A ZA2022/04624 A ZA 2022/04624A ZA 202204624 A ZA202204624 A ZA 202204624A ZA 202204624 B ZA202204624 B ZA 202204624B
Authority
ZA
South Africa
Prior art keywords
gdf15
fusion protein
acting
pharmaceutical composition
long
Prior art date
Application number
ZA2022/04624A
Other languages
English (en)
Inventor
LIM Seyoung
Bong Park Young
Kim Sukyung
Ra SIM Bo
Chong Wonee
Ho Choi Hyun
eun yang Ji
Kyeong JU Mi
Tae Kim Won
Woo Lee Youn
Kim Junhwan
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of ZA202204624B publication Critical patent/ZA202204624B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA2022/04624A 2019-11-26 2022-04-25 Long-acting gdf15 fusion protein and pharmaceutical composition comprising same ZA202204624B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190153680 2019-11-26
PCT/KR2020/016842 WO2021107603A2 (en) 2019-11-26 2020-11-25 Long-acting gdf15 fusion protein and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
ZA202204624B true ZA202204624B (en) 2023-11-29

Family

ID=76130664

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/04624A ZA202204624B (en) 2019-11-26 2022-04-25 Long-acting gdf15 fusion protein and pharmaceutical composition comprising same

Country Status (11)

Country Link
US (1) US20230002460A1 (https=)
EP (1) EP4065597A4 (https=)
JP (1) JP2023503472A (https=)
KR (1) KR20210065057A (https=)
CN (1) CN114729020A (https=)
AU (1) AU2020394255A1 (https=)
BR (1) BR112022010227A2 (https=)
CA (1) CA3161302A1 (https=)
MX (1) MX2022006173A (https=)
WO (1) WO2021107603A2 (https=)
ZA (1) ZA202204624B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117750968A (zh) * 2021-05-21 2024-03-22 株式会社柳韩洋行 用于预防或治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎的包括生长分化因子-15变体的组合物
CA3219645A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
US20240391971A1 (en) * 2021-08-24 2024-11-28 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
CN120530128A (zh) * 2022-11-18 2025-08-22 株式会社柳韩洋行 双功能蛋白及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP2441466B1 (en) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
EP3683228A3 (en) * 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (ko) * 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9862752B2 (en) * 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
RU2017101436A (ru) * 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
AU2015296640B2 (en) * 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US10603359B2 (en) * 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
EP3701969A1 (en) * 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CN114729020A (zh) 2022-07-08
EP4065597A4 (en) 2024-01-24
EP4065597A2 (en) 2022-10-05
CA3161302A1 (en) 2021-06-03
BR112022010227A2 (pt) 2022-09-13
WO2021107603A2 (en) 2021-06-03
AU2020394255A1 (en) 2022-06-09
US20230002460A1 (en) 2023-01-05
KR20210065057A (ko) 2021-06-03
WO2021107603A3 (en) 2021-07-15
JP2023503472A (ja) 2023-01-30
MX2022006173A (es) 2022-06-14

Similar Documents

Publication Publication Date Title
ZA202204624B (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
PE20242299A1 (es) Composiciones agonistas de gip/glp1
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
BRPI0509863A (pt) liberação de fármaco para fundo de olho
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
BRPI0816317A2 (pt) Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno
WO2011009020A3 (en) Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
UA98462C2 (ru) Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
MX2009011900A (es) Curacion de herida diabetica.
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
WO2008157369A3 (en) Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
WO2020198662A8 (en) Clec9a-based chimeric protein complexes
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
ZA202101688B (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
DK1343472T3 (da) Thixotropisk næsespray
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
MX2022005014A (es) Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1.
WO2006088945A3 (en) Granulysin peptides and methods of use thereof
MXPA03006266A (es) Uso de l-carnitina como agente estabilizador de proteinas.
PL1699468T3 (pl) Środek farmaceutyczny zawierający kompleks cynk-hialuronian do leczenia stwardnienia rozsianego
WO2003006002A8 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
DK2024387T3 (da) Peptidsubstans, der forstærker kapillær modstand, farmaceutisk komposition med dens base og fremgangsmåde til applicering deraf
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior